SCHEMBL1935307

SCHEMBL1935307

CC(C)(C)C(Cc1ccc(CO)cc1)NC(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.42
PPARA Q07869 2/20 0.42
MME P08473 5/20 0.41
ACE P12821 5/20 0.41
ACE2 Q9BYF1 4/20 0.41
ADAMTS4 O75173 1/20 0.40
EPHX2 P34913 1/20 0.39
CTRB1 P17538 1/20 0.38
CPA1 P15085 3/20 0.38
PTGS1 P23219 3/20 0.38
PTGS2 P35354 3/20 0.38
LMNA P02545 2/20 0.38
CYP2C9 P11712 2/20 0.38
AKR1C3 P42330 2/20 0.38
CXCR1 P25024 2/20 0.38
CXCR2 P25025 2/20 0.38
ALB P02768 1/20 0.38
ESR1 P03372 1/20 0.38
ALOX5 P09917 1/20 0.38
RARB P10826 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2881400 0.87 ACACB (0.46) PPARAMMEACEACE2CTRB1
SCHEMBL2240306 0.85 PRSS1 (0.44) PPARGPPARAADAMTS4EPHX2CTRB1
SCHEMBL3975272 0.85 MME (0.51) PPARGPPARAMMEACELMNA
SCHEMBL1869960 0.85 MME (0.51) PPARGPPARAMMEACELMNA
SCHEMBL1935741 0.85 MME (0.40) MMEACEACE2CTRB1CPA1
SCHEMBL1936821 0.83 EPHX2 (0.43) MMEACEACE2EPHX2CTRB1
SCHEMBL185475 0.77 PPARG (0.42) PPARGPPARAADAMTS4EPHX2LMNA
SCHEMBL5739824 0.76 ALDH1A1 (0.48) CPA1LMNANPC1RAB9AL3MBTL1
SCHEMBL13935035 0.76 F11 (0.47) CXCR2
SCHEMBL2237876 0.76 FUCA1 (0.42)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2826774-B1 Intermediates for 6-substituted phenoxychroman carboxylic acid derivatives ARRAY BIOPHARMA INC (US) 2016-05-25 EP disclosed
US-8623859-B2 Bradykinin B1 antagonists EVOTEC AG (DE) 2014-01-07 US disclosed
US-20110201589-A1 NEW BRADYKININ B1 ANTAGONISTS EVOTEC AG (DE) 2011-08-18 US disclosed
EP-2331518-A1 NEW BRADYKININ B1 ANTAGONISTS Evotec AG (DE) 2011-06-15 EP disclosed
US-20060276433-A1 Hydrazone derivative DAIICHI PHARMACEUTICAL CO., LTD. (JP) 2006-12-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276433-A1 Hydrazone derivative APP, PRNP, HTT PPARG 507/4885PPARA 619/4885MME 689/4885
US-20110201589-A1 NEW BRADYKININ B1 ANTAGONISTS BDKRB1, BDKRB2, BRS3 PPARG 4780/4885PPARA 4286/4885MME 1089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.